Overview

Essential Hypertension

Status:
Completed

Trial end date:
2012-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate the antihypertensive efficacy of once daily oral administration of ACT 280778 on DBP compared to placebo after 28 days.

Phase:

Phase 2

Details

Lead Sponsor:

Actelion
Idorsia Pharmaceuticals Ltd.

Treatments:

Amlodipine